UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

The New England journal of medicine, 2019-02, Vol.380 (8), p.720-728

2019

Volltextzugriff (PDF)

PCV8 Impct of Comorbidities on Time in Therapeutic Range in Patients with Nonvalvular Atrial Fibrillation

Value in health, 2012-06, Vol.15 (4), p.A112-A113

2012

Volltextzugriff (PDF)

Antenatal Bartter's syndrome: why is this not a lethal condition?

QJM : An International Journal of Medicine, 2008-12, Vol.101 (12), p.927-942

2008

Volltextzugriff (PDF)

Intracranial Murine Tumor Investigation of Radiation and Antiangiogenic Agents using Serial MRI

International journal of radiation oncology, biology, physics, 2010, Vol.78 (3), p.S663-S663

2010

Volltextzugriff (PDF)

OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial

Thrombosis research, 2021-04, Vol.200, p.S12

2021

Volltextzugriff (PDF)

Initiating thromboprophylaxis with low molecular weight heparin and transitioning to oral rivaroxaban

European journal of hospital pharmacy. Science and practice, 2012-04, Vol.19 (2), p.251-251

2012

Volltextzugriff (PDF)

70 Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department

Annals of emergency medicine, 2017-10, Vol.70 (4), p.S29-S30

2017

Volltextzugriff (PDF)

P5139Identification of atrial fibrillation patients who are at high bleeding risk after undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial

European heart journal, 2018-08, Vol.39 (suppl_1)

2018

Volltextzugriff (PDF)

P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

European heart journal, 2017-08, Vol.38 (suppl_1)

2017

Volltextzugriff (PDF)

P3590Rivaroxaban strategies improve the number of days patients remain out of the hospital and event free: A PIONEER substudy

European heart journal, 2017-08, Vol.38 (suppl_1)

2017

Volltextzugriff (PDF)

P6112Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial

European heart journal, 2017-08, Vol.38 (suppl_1)

2017

Volltextzugriff (PDF)

P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial

European heart journal, 2017-08, Vol.38 (suppl_1)

2017

Volltextzugriff (PDF)

Activation of Human Factor VII by Factors IXa and Xa on Human Bladder Carcinoma Cells

Blood, 1989-05, Vol.73 (7), p.1888-1895

1989

Volltextzugriff (PDF)

Isolation and characterization of proteolytic fragments of human factor VIIa which inhibit the tissue factor-enhanced amidolytic activity of factor VIIa

The Journal of biological chemistry, 1993-08, Vol.268 (22), p.16231-16240

1993

Volltextzugriff (PDF)

PCV93 - Outcomes related to variation in hospital pulmonary embolus observation stay utilization

Value in health, 2016-05, Vol.19 (3), p.A56-A56

2016

Volltextzugriff (PDF)

Outcomes related to variation in hospital pulmonary embolus observation stay utilization

Value in health, 2016-05, Vol.19 (3), p.A56-A56

2016

Volltextzugriff (PDF)

Characterisation of Access Site Versus Non-Access Site Bleeding After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation

Heart, lung & circulation, 2018, Vol.27, p.S308-S308

2018

Volltextzugriff (PDF)

The Importance of Residues 195-206 of Human Blood Clotting Factor VII in the Interaction of Factor VII with Tissue Factor

Proceedings of the National Academy of Sciences - PNAS, 1990-09, Vol.87 (18), p.7290-7294

1990

Volltextzugriff (PDF)

The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits

Blood coagulation & fibrinolysis, 1993-10, Vol.4 (5), p.699-706

1993

Volltextzugriff (PDF)

Design and Quantitative Structure−Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa

Journal of medicinal chemistry, 2002-06, Vol.45 (13), p.2749-2769

2002

Volltextzugriff (PDF)

Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins

Blood coagulation & fibrinolysis, 1993-10, Vol.4 (5), p.713-720

1993

Volltextzugriff (PDF)

Mapping the active site of factor Xa by selective inhibitors: An NMR and MD study

Proteins, structure, function, and bioinformatics, 1998-02, Vol.30 (3), p.264-274

1998

Volltextzugriff (PDF)

The role of phospholipids and the factor VII Gla-domain in the interaction of factor VII with tissue factor

Thrombosis and haemostasis, 1992-06, Vol.67 (6), p.679-685

1992

Volltextzugriff (PDF)

Design, synthesis, and structure–activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors

Bioorganic & medicinal chemistry letters, 2003-04, Vol.13 (8), p.1463-1467

2003

Volltextzugriff (PDF)

Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors

Bioorganic & medicinal chemistry letters, 2001-01, Vol.11 (2), p.227-230

2001

Volltextzugriff (PDF)

1 – 25 von 82

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(82)

Sprache

Englisch
(81)
Deutsch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer

PCV8 Impct of Comorbidities on Time in Therapeutic Range in Patients with Nonvalvular Atrial Fibrillation

Antenatal Bartter's syndrome: why is this not a lethal condition?

Intracranial Murine Tumor Investigation of Radiation and Antiangiogenic Agents using Serial MRI

OC-12 D-dimer levels significantly decline in ambulatory cancer patients receiving rivaroxaban compared to placebo: biomarker analysis of the CASSINI trial

Initiating thromboprophylaxis with low molecular weight heparin and transitioning to oral rivaroxaban

70 Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism from the Emergency Department

P5139Identification of atrial fibrillation patients who are at high bleeding risk after undergoing percutaneous coronary intervention: insights from the PIONEER AF-PCI trial

P4565Rivaroxaban treatment strategies reduce not only the first bleeding event, but all (including multiple) bleeding events: A PIONEER Substudy

P3590Rivaroxaban strategies improve the number of days patients remain out of the hospital and event free: A PIONEER substudy

P6112Effect of procedure and lesion characteristics on bleeding and ischemic outcomes among atrial fibrillation patients undergoing percutaneous coronary intervention: results from the PIONEER AF-PCI trial

P4569Rivaroxaban treatment strategies reduce costs associated with rehospitalizations due to bleeding and cardiovascular events: results from the PIONEER AF-PCI trial

Activation of Human Factor VII by Factors IXa and Xa on Human Bladder Carcinoma Cells

Isolation and characterization of proteolytic fragments of human factor VIIa which inhibit the tissue factor-enhanced amidolytic activity of factor VIIa

PCV93 - Outcomes related to variation in hospital pulmonary embolus observation stay utilization

Outcomes related to variation in hospital pulmonary embolus observation stay utilization

Characterisation of Access Site Versus Non-Access Site Bleeding After Percutaneous Coronary Intervention in Patients With Atrial Fibrillation

The Importance of Residues 195-206 of Human Blood Clotting Factor VII in the Interaction of Factor VII with Tissue Factor

The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits

Design and Quantitative Structure−Activity Relationship of 3-Amidinobenzyl-1H-indole-2-carboxamides as Potent, Nonchiral, and Selective Inhibitors of Blood Coagulation Factor Xa

Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins

Mapping the active site of factor Xa by selective inhibitors: An NMR and MD study

The role of phospholipids and the factor VII Gla-domain in the interaction of factor VII with tissue factor

Design, synthesis, and structure–activity relationship of a new class of amidinophenylurea-based factor VIIa inhibitors

Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors

Suchergebnisse filtern